OneMedNet Corporation (ONMD)

Executive Summary / Key Takeaways

• Strategic Amputation for Focus: OneMedNet's decommissioning of its BEAM platform in May 2025 represents a calculated survival move—sacrificing $338K in nine-month subscription revenue to eliminate a failing business and concentrate all resources on iRWD, which grew 343% in Q3 2025. This signals management's willingness to make painful trade-offs, but also reveals the company couldn't afford to run two platforms simultaneously.

• Balance Sheet Trauma Surgery: The approximately 78% reduction in total liabilities from $19.7M to $4.3M in nine months demonstrates aggressive financial restructuring through debt conversions and discounted settlements. This removes immediate bankruptcy risk, but came at the cost of unknown dilution and potentially unfavorable terms that could haunt future equity holders.

• The Palantir Hail Mary: The October 2025 partnership to build iRWD on Palantir's AI infrastructure could transform OneMedNet from a tiny data curator into a scalable platform player. This matters because it addresses the company's fundamental technology and scale disadvantages, but creates critical dependency on a partner with vastly superior bargaining power.

• Going Concern vs. Bookings Mirage: Despite $1.1M in Q3 bookings (up 815%) and 4.5x inbound demand growth, OneMedNet's $100K cash balance and $101.2M accumulated deficit trigger explicit going concern warnings. Even with strong leading indicators, the execution window is measured in weeks, not quarters.

• Extinction-Level Valuation: Trading at approximately 99.1x EV/Revenue with negative book value and -140% gross margins, the stock prices in a flawless transformation that current cash resources cannot support. Any capital raise will likely occur at highly dilutive terms, making the $1.24 stock price a call option on management's ability to secure funding before cash depletion.

Setting the Scene: A Microcap's All-In Bet on AI Data

OneMedNet Corporation, founded in Delaware in November 2015, began as a healthcare software company focused on digital medical image management. For its first eight years, the company operated a dual-platform strategy: iRWD, providing regulatory-grade imaging data to pharmaceutical and AI markets, and BEAM, a medical imaging exchange platform. This bifurcated approach collapsed in May 2025 when management decommissioned BEAM entirely, citing the need to "concentrate efforts on iRWD sales." The decision wasn't strategic optimization—it was financial triage.

The company now operates as a pure-play Real-World Data (RWD) provider, specializing in the secure de-identification, search, and curation of medical imaging archives. Revenue comes from fixed-fee contracts based on data units delivered, primarily serving pharmaceutical companies, device manufacturers, contract research organizations, and AI developers. This narrow focus positions OneMedNet at the intersection of two powerful trends: the FDA and EMA's push for Real-World Evidence in drug approvals, and the AI boom's insatiable demand for high-quality, regulatory-grade training data.

However, OneMedNet's place in the value chain reveals its vulnerability. Unlike integrated giants such as GE HealthCare (GEHC) or Philips (PHG) that bundle imaging hardware with software, or platform players like Tempus AI (TEM) and IQVIA (IQV) that offer multimodal data and analytics, OneMedNet is a specialized tool—more akin to a precision instrument than a comprehensive solution. Its network of 2,130 provider sites and 47 million de-identified patient records is impressive for a microcap, but represents less than 1% of the estimated $10 billion AI medical imaging RWD market. The company's survival depends on whether this specialization becomes a moat or a grave.

Technology, Products, and Strategic Differentiation

The iRWD Platform: Regulatory-Grade as a Double-Edged Sword

OneMedNet's iRWD platform automates the de-identification of medical images while preserving data utility for research—a critical capability in healthcare's privacy-regulated environment. The company claims AI-driven efficiency gains of up to 5x in curation speed, which matters because it reduces manual labor costs and accelerates time-to-delivery for research clients. This efficiency is the core of OneMedNet's value proposition to budget-constrained academic institutions and mid-tier pharma companies.

Yet this technological advantage is narrow. iRWD focuses exclusively on imaging data, while competitors like Tempus AI integrate genomics, clinical records, and imaging into unified platforms. This specialization creates a moat within imaging-specific use cases but becomes a strategic liability as clients increasingly demand multimodal AI training data. The platform's "regulatory-grade" quality—emphasized repeatedly by management—matters for FDA submissions but offers limited differentiation in early-stage research where data breadth trumps perfection.

The Palantir Partnership: Borrowing Scale

The October 2025 agreement for Palantir Technologies (PLTR) to provide infrastructure for the iRWD network represents OneMedNet's most credible path to scalability. Palantir's Foundry platform will enable near real-time data exploration and cohort building , reducing feasibility assessments from weeks to minutes. This matters because it transforms iRWD from a static data delivery service into a dynamic analytics platform, potentially expanding average contract values and improving customer retention.

However, the partnership's structure reveals OneMedNet's weakness. Rather than building proprietary infrastructure, the company is renting scale from a dominant partner. This creates three risks: first, Palantir could extract most of the value created, capping OneMedNet's margins; second, dependency on Palantir's roadmap limits OneMedNet's strategic autonomy; third, if the partnership fails, OneMedNet lacks the capital to build alternative infrastructure. The collaboration is less a strategic alliance and more a lifeline from a stronger swimmer.

Network Effects: Growing but Not Dominant

Since August 2025, OneMedNet added 380 provider sites (22% growth), 13 million patient records (38% growth), and 50 million clinical exams (37% growth). This expansion matters because network effects drive value—each new site increases data diversity, making the platform more attractive to life sciences clients. The company's claim of being "the largest continuously refreshed, regulatory-grade Real-World Data network globally" is ambitious but unverified; GE HealthCare and IQVIA maintain significantly larger datasets through integrated hardware and service relationships.

The network's quality over quantity strategy could be defensible if imaging data commands premium pricing. However, the 109% iRWD revenue growth on a base of just $363K for nine months suggests either low pricing power or minimal data volumes. The 4.5x increase in inbound demand is encouraging, but without disclosure of conversion rates or sales cycle length, it may reflect curiosity rather than committed spending.

Financial Performance: Growth Masking Decay

Revenue: The Illusion of Progress

OneMedNet reported $177K in Q3 2025 revenue, a 25% year-over-year increase that appears healthy until dissected. iRWD revenue surged 343% to $177K, while BEAM revenue collapsed 100% to zero. For the nine-month period, total revenue fell 24% to $468K as BEAM's $338K decline overwhelmed iRWD's $189K gain. This matters because it reveals the strategic pivot's true cost: the company is trading a declining but existent revenue stream for a growing but insufficient one.

The growth quality is suspect. iRWD's $363K nine-month revenue implies average quarterly bookings of roughly $121K—far below the $1.1M Q3 bookings figure. This discrepancy suggests either massive seasonality, multi-year contract structures with minimal upfront revenue, or bookings that won't convert to recognized revenue quickly. Management's commentary attributes growth to "enhanced focus on iRWD sales leading to increased customer deliveries," but provides no detail on customer count, contract sizes, or pricing trends.

Margins and Cost Structure: Deteriorating Economics

Cost of revenue as a percentage of revenue increased 66% in Q3 and 101% for nine months, a catastrophic deterioration. This matters because it indicates negative operating leverage—costs are growing faster than revenues, the opposite of what should happen in a software business. Management blames the BEAM decommissioning (lower subscription revenue without immediate cost savings) and higher iRWD data and personnel costs to support sales growth.

The implication is stark: iRWD is not a scalable software business in its current form. Data curation and personnel costs rise with revenue, suggesting a services-heavy model rather than true platform economics. General and administrative expenses fell 24% in Q3, showing discipline, but sales and marketing expenses jumped 117% to drive iRWD growth. This trade-off—cutting overhead while burning cash to acquire customers—is sustainable only with ample capital reserves, which OneMedNet lacks.

Profitability: An Accounting Mirage

OneMedNet reported $741K net income in Q3 versus a $2.058M loss prior year, and $339K for nine months versus a $7.756M loss. This matters because the improvement is entirely non-operational. A $1.9M gain on troubled debt restructurings in Q3 and $5.569M for nine months—generated from settling deferred underwriter fees and restructured trade payables—created paper profits while operations burned cash.

Operating losses remain severe: $2.2M for Q3 and $6.6M for nine months. The company has never generated positive operating cash flow since inception. The accumulated deficit of $101.2M as of September 30, 2025, represents approximately 1.6x the current market cap, a staggering burden that future equity raises must address. Management's assertion that they "may not be able to secure such financing in a timely manner or on favorable terms" is not boilerplate—it's a direct warning that dilution or bankruptcy are both on the table.

Balance Sheet and Liquidity: The Countdown Clock

The Liability Slashing: Necessary but Costly

OneMedNet's balance sheet transformation is dramatic. Total liabilities fell from $19.7M in December 2024 to $6.2M in June 2025, then to $4.3M by September 2025—an $14.3M reduction in nine months. This matters because it removes immediate covenant violations and creditor pressure, but the methods raise red flags. Debt conversions, vendor repayments, and "highly discounted debt settlements" including PIPE Notes , loan extensions, and shareholder loans converted to common stock suggest distressed exchanges where creditors took equity at fire-sale prices.

The $1.9M additional liability reduction in Q3 2025 came alongside the $1.9M gain on debt restructuring, indicating these were negotiated settlements rather than operational improvements. While survival justifies such tactics, they likely created significant dilution and signaled to future lenders that OneMedNet's creditworthiness is severely impaired. The company's ability to raise new debt at reasonable terms is effectively zero.

Cash Position: Insufficient for Purpose

OneMedNet held $100K in cash and $600K in Bitcoin as of September 30, 2025. Management explicitly states this is "not adequate to fund its operations through at least twelve months from the date these condensed consolidated financial statements were available for issuance." This matters because it establishes a hard deadline: the company must raise capital before year-end 2025 or face insolvency.

The Bitcoin holdings, initiated in July 2024 as a "treasury strategy," expose the company to significant volatility on an already fragile balance sheet. While the $600K represents 85% of liquid assets, Bitcoin's price swings could wipe out months of runway overnight. This is not treasury management—it's speculation with money the company cannot afford to lose.

Capital Raising: The Inevitable Crunch

In October 2025, OneMedNet raised $1.6M from selling common stock to Yorkville and $60K from warrant exercises. This matters because it shows management is already tapping emergency funding sources. Yorkville's involvement as a repeat investor suggests limited alternative capital providers. The terms were undoubtedly dilutive, though undisclosed.

Management's plan to "raise additional working capital through equity or debt offerings" faces harsh reality: with negative book value, no operational cash flow, and a going concern warning, any equity raise will be highly dilutive, and any debt will carry punitive interest rates. The company is in a race to grow iRWD revenue fast enough to justify a capital raise before cash runs out.

Competitive Positioning: A Minnow Among Whales

Direct Comparison: Scale Disadvantage

OneMedNet's $177K quarterly revenue compares to GE HealthCare's $5.1B, Philips' $4.3B, Tempus AI's $334M, and IQVIA's $4.1B. This matters because scale drives everything in healthcare data: procurement leverage with hospitals, R&D investment capacity, sales force reach, and data network effects. OneMedNet's 2,130 sites sound impressive until IQVIA's billions of records and GE HealthCare's global installed base of imaging equipment are considered.

The company's -140% gross margin versus competitors' 34-62% margins reveals a fundamental business model problem. GE HealthCare's 15% operating margin and IQVIA's 14% margin reflect scalable platforms where incremental revenue costs little to deliver. OneMedNet's costs rise with revenue, suggesting a manual, labor-intensive curation process rather than true AI automation. This is the difference between a software company and a services business masquerading as one.

Moats and Vulnerabilities

OneMedNet's claimed moat is "regulatory-grade" imaging data quality and a "continuously refreshed" network. This matters because FDA submissions require data provenance and quality documentation that generic aggregators cannot provide. However, competitors are building similar capabilities. GE HealthCare's Edison AI platform and Philips' HealthSuite Imaging both offer regulatory-compliant data curation, while Tempus AI and IQVIA have deeper relationships with pharma sponsors who ultimately pay for RWD.

The Palantir partnership could create a temporary technology moat by enabling "near real-time" cohort building and reducing feasibility assessments from weeks to minutes. But this advantage is borrowed, not owned. If Palantir integrates similar capabilities directly with larger RWD providers, OneMedNet's edge evaporates. The partnership's exclusivity terms, undisclosed, will determine whether this is a true differentiator or just a vendor relationship.

Customer Concentration and Pricing Power

OneMedNet's customer base is not disclosed, but the microcap scale suggests high concentration risk. The 4.5x increase in inbound demand is promising, but without data on sales conversion or pricing trends, it's impossible to assess whether this reflects genuine product-market fit or simply increased market curiosity. The company's ability to win a "top five medical device leader" as an evergreen client is encouraging, but one large customer loss would be catastrophic at this revenue scale.

Outlook, Guidance, and Execution Risk

Management's Implicit Guidance: Survive Then Thrive

OneMedNet provides no formal revenue or profitability guidance, which matters because it signals uncertainty about execution. Management's explicit statements—that cash is insufficient for 12 months and that financing may not be available on favorable terms—constitute guidance of a different sort: a warning that the company is in a fight for survival.

The strategic direction is clear: expand the iRWD network, convert inbound demand to subscription revenue, and leverage the Palantir partnership to improve unit economics. However, the timeline is compressed by cash constraints. The company must achieve operational cash flow breakeven before accessing additional capital, a feat that seems distant given $6.6M in nine-month operating losses against $363K in iRWD revenue.

Critical Execution Variables

Three factors will determine success or failure:

1. Capital Raise Timing and Terms: Can OneMedNet secure funding before cash depletion? Any delay or unfavorable terms (high dilution, warrants, convertible debt with ratchets) will severely impair equity value.

2. Palantir Integration Velocity: Will the partnership deliver measurable improvements in sales cycles, contract values, and gross margins by Q1 2026? Slow integration will waste precious time and cash.

3. iRWD Unit Economics: Can the company demonstrate that iRWD revenue growth eventually outpaces cost growth, achieving positive contribution margins? Current cost of revenue trends suggest this is not happening yet.

Downside Scenarios

If OneMedNet fails to raise capital by Q1 2026, insolvency is likely. Even with a successful raise, if iRWD revenue doesn't scale beyond $1M quarterly by mid-2026, the company will face another cash crisis. Competitive displacement is a slower but real risk—if GE HealthCare or IQVIA launch competing imaging RWD platforms with better AI integration, OneMedNet's window of opportunity closes.

The Bitcoin treasury strategy adds a unique risk: a 50% Bitcoin price decline would reduce liquid assets by $300K, potentially cutting runway by a month. This is an unconscionable risk for a company with $100K cash.

Valuation Context: Pricing in the Impossible

At $1.24 per share, OneMedNet trades at a $63.4M market capitalization and $63.7M enterprise value, representing approximately 99.1x EV/Revenue on TTM sales of $643K. This matters because the multiple assumes revenue will grow 100x while achieving software-company margins, a transformation that current cash resources cannot fund.

Traditional valuation metrics are meaningless: negative book value (-$0.08 per share) and negative gross margins (-140%) render P/B and margin-based comparisons useless. The -197% return on assets reflects a business destroying capital, not creating it. The 0.29 current ratio and 0.15 quick ratio indicate severe liquidity stress.

Peer comparisons highlight the valuation chasm. GE HealthCare trades at 2.24x EV/Revenue with 14% operating margins. Tempus AI trades at 11.57x with 62% gross margins. Even money-losing Tempus AI has $1B+ in cash to fund growth. OneMedNet's approximately 99.1x multiple with $700K in liquid assets and -140% gross margins is not a premium—it's a lottery ticket pricing in a miracle.

The only relevant valuation metric is cash runway: with $700K in liquid assets and $2.2M quarterly operating cash burn, the company has approximately 0.3 quarters of runway—less than one month—without the October 2025 $1.6M Yorkville injection. Pro forma liquidity of $2.3M provides roughly one quarter of runway. This is the valuation that matters: can the company survive long enough to prove its model?

Conclusion: A Call Option on Desperation

OneMedNet is executing the right strategic moves for the wrong balance sheet. The BEAM decommissioning, iRWD focus, Palantir partnership, and liability reduction are all rational steps for a company with resources and time. But OneMedNet has neither. The 343% iRWD growth and 815% bookings increase are impressive but irrelevant if the company cannot fund the next quarter's operations.

The investment thesis is binary: either OneMedNet secures dilutive but sufficient capital to reach cash flow breakeven on iRWD growth, or it exhausts its runway and enters bankruptcy. The Palantir partnership provides a credible technology path, but not a financial one. The competitive position is defensible only if the company achieves scale before larger players target its niche.

For investors, the $1.24 stock price represents a call option on management's ability to perform two near-impossible tasks simultaneously: raise capital on acceptable terms and scale iRWD revenue 10x while improving unit economics. The odds are long, the timeline is short, and the downside is near-total. This is not a turnaround story—it's a survival story where success means living to fight another day, and failure means zero. The critical variables to monitor are the terms of the next capital raise and the Q4 2025 iRWD revenue run-rate. If both disappoint, the stock's appropriate valuation is not $1.24, but $0.